Alembic Pharmaceuticals Ltd.

AS ON 15:56 PM | 15 Jul
AS ON 16:01 PM | 16 Jul
NSE
BSE
524.40-1.95-0.37%
Today's Trend
Low
520.05
High
527.95
Volume
16047.00
Open
527.00
Prev Close
526.35
524.30-3.25-0.61%
Today's Trend
Low
520.35
High
528.25
Volume
3541.00
Open
525.00
Prev Close
527.55
x
Add to Portfolio
Add to Watchlist

Technical Chart

  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
Bid
Offer

Mkt Cap (₹ Cr.)

Face Value (₹)

P/E (x)
EPS-TTM(₹)
P/B (x)
BV/Sh(x)
Div. Yield(%)
52Wk L/H

Alembic Pharmaceuticals Ltd.
News & Recos

  • Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
    The exchange is hereby informed that the Company will hold Post Results Conference Call on 29th July, 2019 as per the enclosed details. We request you to kindly take the same on record.
  • Board Meeting Intimation for To Consider Unaudited Financial Results For The Quarter Ended 30Th June, 2019
    ALEMBIC PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/07/2019 ,inter alia, to consider and approve With reference to the captioned matter, the exchange is hereby informed that a Meeting of Board of Directors of the Company will be held on Monday, 29th July, 2019, inter alia to consider and approve Unaudited Financial Results of the Company for the quarter ended 30th June, 2019. Pursuant to the Companys Code of Conduct for Regulating, Monitoring and Reporting of Trading by Designated Persons and their Immediate Relatives, the trading window for dealing in securities of the Company which was closed from 1st July, 2019, will re-open 48 hours after the declaration of the financial results on 29th July, 2019. We request you to kindly take the same on record.
  • Buy Alembic Pharmaceuticals, target Rs 675: IIFL
    Alembic Pharmaceuticals is a midcap company, operating in pharmaceuticals and health care sector.
    Buy
  • Alembic Pharma gets USFDA nod for seizure treatment drug
    The approved product is therapeutically equivalent to the reference listed drug Klonopin orally disintegrating tablets of Hoffmann-La Roche, Inc.
  • Buy Alembic Pharmaceuticals, target Rs 590: HSBC
    Alembic Pharmaceuticals is a midcap company, operating in pharmaceuticals and health care sector.
    Buy
MORE FROM NEWS & RECOS

Alembic Pharmaceuticals Ltd. Earnings
(Figures in Rs. Cr.)

Sales

Other Operating
Income

Operating Profit

Other Income

EBITDA

Interest

Depreciation

Tax

Net Profit

EPS (₹)

Mar 2019
% Chg (Quarterly)
% Chg (Yearly)
Peer Range
Trend
926.95
-8.96
8.63
0.00
7163.92
0.00
0.00
0.00
-0.39
282.40
178.04
-26.50
2.78
-111.34
1972.07
3.37
-4.26
426.56
-6.58
281.53
181.41
-26.18
4.34
-111.34
1972.07
5.08
-14.62
279.10
-0.54
1315.65
29.95
3.10
-5.13
-0.03
510.28
14.90
-62.75
-61.32
-34.10
299.84
123.70
-27.16
31.89
-152.00
635.88
6.58
-26.97
32.13
-24.13
53.28

Alembic Pharmaceuticals Ltd. Stock Performance

Period:
LTP
%Change
Trend
524.40
-0.37
440.85
-1.28
441.80
-0.82
936.20
-0.37
922.95
-0.72
1950.50
-2.64
5937.20
0.69
3193.90
-0.02
511.85
-0.96
453.70
-3.11
4759.20
-3.05

Alembic Pharmaceuticals Ltd. Financial Performance

LTP
(₹)
Market Cap
(Cr.)
Price to
Book
Price to
Earnings
PAT
Margins
RoE%
RoA%
Debt to
Equity
Avg. Cost
of Funds%
Current
Ratio
524.40
9869.57
3.63
16.15
0.00
0.00
0.00
0.00
0.00
0.00
511.85
9318.71
2.68
13.95
0.00
0.00
0.00
0.00
0.00
0.00
936.20
11770.19
3.76
25.92
0.00
0.00
0.00
0.00
0.00
0.00
922.95
8072.56
3.60
20.60
0.00
0.00
0.00
0.00
0.00
0.00
440.85
12425.08
2.22
8.01
0.00
0.00
0.00
0.00
0.00
0.00
453.70
7218.77
1.50
48.92
0.00
0.00
0.00
0.00
0.00
0.00
5937.20
13538.46
6.11
34.68
0.00
0.00
0.00
0.00
0.00
0.00
4759.20
7906.71
5.14
61.77
0.00
0.00
0.00
0.00
0.00
0.00
441.80
6072.51
5.20
21.30
29.60
23.59
24.27
0.00
0.00
1.13
3193.90
14560.51
10.56
33.99
0.00
0.00
0.00
0.00
0.00
0.00
1950.50
4893.16
16.25
89.76
0.00
0.00
0.00
0.00
0.00
0.00

Alembic Pharmaceuticals Ltd. Financial Comparison with peers

Management Efficiency

Return On Equity (%)

Return On Assets (%)

Return On Capital Employed (%)

Fixed Assets Turnover (x)

Profitability & Growth

Gross Profit Margin (%)

Operating Profit Margin (%)

Net Profit Margin (%)

Financial Strength
Liquidity

Quick Ratio (x)

Current Ratio (x)

Cash Ratio (x)

Solvency

Debt Equity Ratio (x)

Coverage Ratios

Cash Flows to Long Term Debt (x)

Alembic Pharmaceuticals Ltd.
Peer
Average
Peer Range
Trend
21.49
10.20
-99.01
65.59
12.35
7.75
-15.79
86.02
14.83
8.84
-130.86
28.02
1.20
0.98
0.00
3.24
19.27
-3.73
-980.00
49.74
22.20
2.16
-896.19
53.68
14.85
12.02
-43.52
180.43
0.93
1.69
0.40
9.50
1.78
2.45
0.85
9.50
0.18
0.24
-0.52
1.40
0.18
0.48
0.00
13.27
1.31
4.19
0.00
45.52

Alembic Pharmaceuticals Ltd. Share Holding

  • Categories
    No. Of Shares
    %
  • Promoters
    136,552,093
    72.44
  • NoOfShares
    188,515,914
    100.00
  • GeneralPublic
    18,642,046
    9.89
  • ForeignInstitutions
    17,905,412
    9.50
  • NBanksMutualFunds
    9,695,449
    5.14
  • Others
    4,074,302
    2.16
  • ForeignPromoter
    1,006,980
    0.53
  • FinancialInstitutions
    639,632
    0.34

Mutual Fund Ownership

Category
Rating
No. of shares
%Change in Shares
(MOM basis)
% of AUM
Amount Invested
(in ₹ Cr)
Equity: ELSS
1689516
0.00%
1.34%
85.95
Equity: Multi Cap
1034676
0.00%
1.32%
52.64
Equity: Mid Cap
1000000
0.00%
0.75%
50.88
Equity: Large & MidCap
979329
0.00%
1.52%
49.82

Liquid, Ultra Short Term funds and FMPs are not taken into account.

More Schemes

About Alembic Pharmaceuticals Ltd.

Alembic Pharmaceuticals Ltd., incorporated in the year 2010, is a Mid Cap company (having a market cap of Rs 9883.89 Crore) operating in Pharmaceuticals and health care sector.

Alembic Pharmaceuticals Ltd. key Products/Revenue Segments include Pharmaceuticals which contributed Rs 3533.84 Crore to Sales Value (96.54 % of Total Sales), Export Incentives which contributed Rs 88.18 Crore to Sales Value (2.40 % of Total Sales), Royalty Income which contributed Rs 30.67 Crore to Sales Value (0.83 % of Total Sales) and Other Operating Revenue which contributed Rs 7.58 Crore to Sales Value (0.20 % of Total Sales)for the year ending 31-Mar-2019.

For the quarter ended 31-03-2019, the company has reported a Consolidated sales of Rs 926.95 Crore, down -8.96 % from last quarter Sales of Rs 1018.15 Crore and up 8.63 % from last year same quarter Sales of Rs 853.31 Crore Company has reported net profit after tax of Rs 131.48 Crore in latest quarter.

The company’s top management includes Dr.Archana Hingorani, Mr.Chirayu Amin, Mr.K G Ramanathan, Mr.Paresh Saraiya, Mr.Pranav Amin, Mr.Pranav Parikh, Mr.R K Baheti, Mr.Shaunak Amin. Company has K S Aiyar & Co. as its auditoRs As on 31-03-2019, the company has a total of 188,515,914 shares outstanding.

Loading data...
Text Size:AAA

*

Markets Data
GetET MarketsAPP